{'fraction_non_alphanumeric': 0.032490974729241874, 'fraction_numerical': 0.016245487364620937, 'mean_word_length': 5.166666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Is T790M mutation the key in development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)?

Over the last 2 decades, a number of new approaches were proposed in diagnosis and treatment of non-small cell lung cancer (NSCLC), which comprises about 80 to 85% of all lung cancers. For its diagnosis, gene expression profiling has recently been suggested as a predictive and prognostic biomarker in early-stage NSCLC (1). For its treatment, multiple modalities have been developed and introduced into clinical practice.